First human test for new schizophrenia shot
Disease control
Not yet recruiting
This early-stage study aims to understand how a new long-acting injectable medication for schizophrenia moves through the body and how safe it is. It will involve 48 adults with stable schizophrenia who will receive a single injection. The main goal is to measure drug levels in t…
Phase: PHASE1 • Sponsor: Anxo Pharmaceutical Co., Ltd. • Aim: Disease control
Last updated Mar 27, 2026 12:40 UTC